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Abstract
Rapid and reliable diagnosis of inﬂuenza is essential for identiﬁcation of contagious patients and effective patient management. Near-
patient assays allow establishment of the diagnosis within minutes in young children, and this study aimed to evaluate near-patient assays
in relation to the patient’s age. A total of 194 patients with laboratory-conﬁrmed inﬂuenza A/H3N2 virus infection, diagnosed within
a prospective cohort study, were included. Cryopreserved nasopharyngeal swabs collected from these patients were tested by four
near-patient assays (Binax Now Inﬂuenza A&B, Quick S-Inﬂu A/B, Inﬂu-A&B Respi-Strip, and Actim Inﬂuenza A&B). The main outcome
measure was sensitivity of the near-patient assays in relation to the age of patients. The Binax Now, Quick S-Inﬂu, Inﬂu-A&B Respi-Strip
and Actim assays had overall sensitivities of 19%, 18%, 26%, and 40%, respectively. The estimated sensitivity for inﬂuenza A/H3N2 virus
detection in nasopharyngeal swabs was 17–56% in children 1 year of age and decreased to 8–22% in patients 80 years of age (logistic
regression). The sensitivity of the Inﬂu-A&B Respi-Strip and Actim assays decreased signiﬁcantly with increasing age (p 0.014 and
p 0.033, respectively (logistic regression)), a trend for decrease was observed for the Binax Now assay (p 0.074 (logistic regression)),
and the low sensitivity of the Quick S-Inﬂu assay was similar in children and adults. Less than one-fourth of diagnosed inﬂuenza A/H3N2
virus infections can be identiﬁed in elderly patients using a near-patient assay. Consequently, near-patient assays are of limited value for
conﬁrming the diagnosis when inﬂuenza is clinically suspected in adults. Antiviral therapy and additional diagnostic procedures cannot be
withheld on the basis of a negative near-patient assay result, particularly in adult patients.
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Introduction
An estimated 200 000 hospitalizations and 36 000 deaths are
attributable to inﬂuenza annually in the USA alone [1].
Elderly patients are most affected; that is, inﬂuenza-related
deaths, hospitalizations and use of health services are
recorded mostly for patients >65 years of age [2,3]. The
virus can spread particularly rapidly in care homes, poten-
tially affecting 60% of residents [4]. Accurate and rapid diag-
nosis of inﬂuenza is essential for identiﬁcation of contagious
patients and effective management of cases of inﬂuenza.
Management decisions regarding infection control, referral to
specialized units, use of additional diagnostic procedures and
administration of antiviral therapy have to be made at the
point of ﬁrst contact with the patient. The antiviral drugs
oseltamivir and zanamivir are highly effective against inﬂu-
enza A and B viruses, but must be administered as soon as
possible, at least within the ﬁrst 48 h after the onset of the
acute respiratory disease, to be effective [5,6].
Reliable identiﬁcation of cases of inﬂuenza within this short
time frame is challenging. The sensitivity and speciﬁcity of the
clinical diagnosis of inﬂuenza are as low as 64–77% and 55–
67%, respectively, even during the peak of the ﬂu season [7,8].
Laboratory-based assays for the diagnosis of inﬂuenza, e.g.
detection of virus or viral genome in respiratory secretions
via virus culture or inﬂuenza virus-speciﬁc PCR, are highly
sensitive and speciﬁc [9]. Test results, however, usually
become available more than 48 h after sample collection and
several days after onset of the disease.
Near-patient diagnostic assays provide results within
30 min, and almost 20 commercial assays are currently avail-
able for the diagnosis of inﬂuenza [10]. The speciﬁcity of
these assays is well above 95% [10], but the values for test
sensitivity stated in the manufacturers’ product information
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differ, sometimes considerably, from those described in
investigator-initiated studies [11,12].
Previously, we observed that the sensitivity of a labora-
tory-based diagnostic assay for detection of inﬂuenza virus
or viral particles in respiratory specimen decreases signiﬁ-
cantly with increasing age of the patient [9]. Manufacturer-
initiated evaluations of near-patient assays, to our knowledge,
concern exclusively respiratory specimens collected from
very young children (information provided by Binax Inc.,
Coris Bioconcept, Medix Biochemica, and Denka Seiken).
However, studies that revealed a clearly lower sensitivity of
these assays included samples from all age groups [11,12].
Thus, it was suspected that the patient’s age may inﬂuence
the detection rates achieved by near-patient assays. It was
therefore the aim of the present study to evaluate in parallel
several different near-patient assays by testing respiratory
specimens from both children and adults with laboratory-
conﬁrmed inﬂuenza A virus infection.
Materials and Methods
Patient samples
Virological surveillance of respiratory virus activity in Austria
is based on respiratory specimen collected by sentinel physi-
cians (physicians of inpatient and outpatient hospital units,
general practitioners and paediatricians throughout Austria)
within two surveillance systems—the Diagnostic Inﬂuenza
Network Austria (DINOE) and the Respiratory Network
(RNW). The inclusion criterion for the DINOE is an inﬂu-
enza-like illness (acute onset of fever with respiratory and
constitutional symptoms) and that for the RNW is the clini-
cal diagnosis of an acute respiratory tract infection including
rhinitis, bronchitis and pneumonia. These two surveillance
systems include patients of all age groups with acute respira-
tory tract infections. Nasopharyngeal swabs are taken by
experienced physicians, with a swab being taken from both
the nose and the throat of the patients. The swab content
is tranferred into 1000 lL of transport medium consisting of
minimal essential medium (MEM) (GIBCO; Life Technologies,
Lofer, Austria) and discarded thereafter. All clinicians partici-
pating in the two surveillance systems were provided with
transport medium by the Clinical Institute of Virology, Medi-
cal University of Vienna. Immediately after delivery, the clini-
cal samples were vortexed vigorously, diluted in MEM
(1 : 2), and split into aliquots before being screened for
inﬂuenza A and B viruses by virus isolation or RT-PCR, or
both.
For the present investigation, inﬂuenza A/H3N2-positive
samples that were collected during the period of epidemic
activity of inﬂuenza in the winter seasons of 2005–2006 and
2006–2007 were tested and cryopreserved for later analysis.
Samples were frozen at )70C and thawed only once for
the present investigation. Only samples collected from
patients younger than 10 years or older than 35 years were
included. The separation of patients into these two age
groups was done for practical reasons. In the two surveil-
lance networks DINOE and RNW, the highest consultation
rates were observed in patients younger than 10 years or
older than 35 years during the inﬂuenza season. The aim was
therefore to optimize the project for the comparative
assessment of near-patient assays in these age groups. For
the purpose of standardization, only inﬂuenza A virus-posi-
tive samples were included. The virological diagnosis was
established in all patients by inﬂuenza A virus-speciﬁc PCR
and conﬁrmed by virus isolation.
Virus isolation in tissue culture and typing of the isolates
Virus isolation in tissue culture and typing of the isolates
were carried out on Madin–Darby canine kidney cells (Amer-
ican Type Culture Collection, Manassas, VA, USA) according
to standard procedures [13]. The inﬂuenza A virus strains
isolated during the study period were typed and subtyped as
described previously [14].
Detection of inﬂuenza A virus RNA sequences
Viral genome RNA was detected in clinical samples by a
nested PCR assay as described previously [9]. In brief, viral
RNA was extracted from 140 lL of the clinical sample by
using QIAamp Viral RNA mini kits (QIAGEN, Hilden, Ger-
many). For reverse transcription and the two steps of the
nested PCR, inﬂuenza A virus type-speciﬁc primers that bind
to the highly conserved region of the inﬂuenza A virus gen-
ome coding for non-structural protein 1 were used. Each
PCR experiment included two to ﬁve positive controls, sev-
eral negative controls, and two to three respiratory virus-
positive specimens (respiratory syncytial virus, enteroviruses,
rhinoviruses, coronavirus, parainﬂuenza viruses or adenovi-
ruses) interposed between the samples tested. Quantiﬁcation
of inﬂuenza A virus-speciﬁc RNA in clinical samples was
done as described previously [15].
Detection of inﬂuenza virus antigen by ELISA
The in-house ELISA used for detection of inﬂuenza virus
antigen was carried out as described previously [9,16].
Detection of inﬂuenza virus antigen using near-patient
assays
The commercially available rapid diagnostic tests are screen-
ing tests for inﬂuenza A and B virus infections that can
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provide results within 30 min. These tests are immunoassays
that detect inﬂuenza viral antigen in respiratory specimens
with the use of virus-speciﬁc antibodies. They may also be
referred to as rapid tests or point-of-care tests. All ofﬁcial
Austrian representatives of the manufacturers of assays for
the near-patient diagnosis of inﬂuenza (n = 4) were invited
to participate in the present study by donating kits sufﬁcient
in number for testing 30 clinical specimens from children and
50 clinical specimens from adults. Table 1 summarizes
selected characteristics of the four rapid assays evaluated in
the present study. According to the manufacturers’ product
informations, nasopharyngeal swabs in transport medium
may be used without signiﬁcant loss of sensitivity and speci-
ﬁcity of these assays. A total of 200 lL of clinical specimen
was used for each test. This quantity equals the average
volume of nasopharyngeal secretion collected by a standard
cotton swab (Medix Biochemica and Denka Seiken, personal
communication). Clinical specimens from 194 patients were
included for the evaluation of the four assays. The volume of
the 194 samples was not sufﬁcient for testing by all four
assays. Therefore, samples were assigned randomly within
the two age groups to the four diagnostic assays to allow
equal numbers of samples to be tested with the four assays.
Statistical analysis
Logistic regression was used to analyse the relationship
between the test results obtained by the four near-patient
diagnostic assays and the patients’ age. Receiver operating
characteristic (ROC) curves were used to assess the extent
to which the concentration of inﬂuenza A virus-speciﬁc RNA
in clinical samples may be associated with a false-negative
result in a near-patient assay.
Comparison of near-patient assay results, with respect to
concentration of inﬂuenza A virus, was carried out using the
Mann–Whitney U-test. In all analyses, a p-value of <0.05 was
considered to be statistically signiﬁcant. All statistical analyses
were performed using the commercial software SPSS 15.0
(SPSS Inc., Chicago, IL, USA).
Results
Detection of inﬂuenza A viruses in clinical specimens
All clinical specimens used for the present evaluation of
near-patient assays were positive for inﬂuenza A/H3N2 for
the purpose of standardization, which corresponds to the
seasonal predominance of inﬂuenza A/H3N2 during the study
period [14] (http://www.eiss.org). These specimens were col-
lected from patients 1–101 years of age. The mean age of
the children was 4.6 years (standard deviation (SD), 2.9 years)
and that of the adults was 57.6 years (SD, 15.9 years). Seven
of these patients were younger than 1 year and 20 were
older than 80 years. The Binax Now Inﬂuenza A&B, Quick
S-Inﬂu A/B, Inﬂu-A&B Respi-Strip, and Actim Inﬂuenza A&B
had overall sensitivities of 19%, 18%, 26%, and 40%, respec-
tively. As shown in Fig. 1, the sensitivity of the three more
sensitive assays decreased with increasing age of the patients,
whereas the low sensitivity of the Quick S-Inﬂu A/B assay
was constant throughout all ages, from young children to
elderly patients. The estimated probability of detecting inﬂu-
enza A virus in clinical specimens that tested positive accord-
ing to RT-PCR was 17–56% in children 1 year of age, and
decreased to 8–22% in patients 80 years of age. The sensitiv-
ity of the near-patient assays with comparably high overall
sensitivity (Inﬂu-A&B Respi-Strip and Actim Inﬂuenza A&B)
decreased signiﬁcantly with increasing age (Table 2). A trend
for lower sensitivity in adults was observed also for the Bin-
ax Now Inﬂuenza A&B.
TABLE 1. Selected characteristics of the near-patient assays evaluated in the present study
Assay Manufacturer
Inﬂuenza
type
detected
Recommended
specimen
Recommended
incubation
period
Sensitivity for inﬂuenza
A viruses
Speciﬁcity for inﬂuenza
A viruses
Manufacturer’s
product
information (%)
Investigator-
initiated
studies (%)
Manufacturer’s
product
information (%)
Investigator-
initiated
studies (%)
Binax Now
Inﬂuenza A&B
Binax Inc.,
Portland, ME, USA
A and B Nasal wash, nasal
aspirate,
nasopharyngeal
swabs
15 min 100 59–80 [12,22,23] 92–93 98–99 [12,22]
Quick S-Inﬂu
A/B ‘Seiken’
Denka Seiken Co.,
Ltd, Tokyo, Japan
A and B Nasal swab, nasal
aspirate
15 min 90–93 81 [11] 98–99 96 [11]
Inﬂu-A&B
Respi-Strip
Coris BioConcept,
Gembloux, Belgium
A and B Nasopharyngeal
aspirates,
washings or swabs
15 min 99 ND 88 ND
Actim Inﬂuenza
A&B
Medix Biochemica
Ab, Kauniainen,
Finland
A and B Nasal swabs and
nasopharyngeal
aspirates
10 min 88–92 ND 99–100 ND
ND, not done—only samples positive for inﬂuenza A viruses were included in these investigations.
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In vitro sensitivity of near-patient diagnostic assays
In order to evaluate the sensitivity of the near-patient assays
under standardized conditions, cell-adapted virus stock
preparations of inﬂuenza A/Wisconsin/67/05(H3N2), A/New
Caledonia/20/99(H1N1) and B/Jiangsu/10/03 were tested with
three of the four near-patient assays and, for comparison,
with an in-house antigen-ELISA and an in-house RT-PCR
assay (in vitro evaluation of the Quick S-Inﬂu A/B assay was
not possible because the manufacturer provided kits for only
80 tests). These preparations were diluted in ten-fold steps
in MEM, vortexed vigorously, separated into ﬁve aliquots,
and tested with the ﬁve assays. In these experiments, the
detection limits of the three near-patient assays and the
in-house antigen-ELISA ranged between 102 and 106 tissue
culture infective doses (TCID50)/mL, whereas RT-PCR had
an in vitro sensitivity of 0.01–0.001 TCID50/mL (Table 3). The
in vitro sensitivity of the Actim Inﬂuenza A&B assay was one
log titre higher for the inﬂuenza A/H3N2 strain used than
the sensitivity of the other near-patient assay. The sensitivity
of all assays used was lower for the inﬂuenza A/H1N1 than
for the inﬂuenza B virus strain used.
Quantiﬁcation of inﬂuenza A virus-speciﬁc RNA in clinical
specimens
Clinical samples with a sufﬁcient volume available (n = 53)
were additionally tested using a quantitative inﬂuenza A
virus-speciﬁc RT-PCR, for comparison with the qualitative
results obtained by the near-patient assays. Positive results
of the near-patient assays were associated with signiﬁcantly
higher concentrations of inﬂuenza A virus RNA in the clinical
samples than negative results (Table 4). The ROC cut-off
points for a predicted sensitivity of 100% for near-patient
assays in detecting inﬂuenza A virus in clinical samples were
similar to the in vitro sensitivities observed when testing virus
stock preparations of inﬂuenza A virus (compare Tables 3
and 4). The area under the ROC curve for a positive near-
patient assay result was similar for all four assays and ranged
between 0.81 and 0.88 (Fig. 2).
Discussion
A low sensitivity of near-patient assays may have been sus-
pected on the basis of previous studies, but the present
TABLE 2. Sensitivity of the near-patient diagnostic assays with respect to the age of the patients
Diagnostic assay/manufacturer
No. of
specimens
Sensitivity (%)
Mean age of the patients
(SD) (years)
pa
0–10 years >35years Negative Positive
Binax Now Inﬂuenza A&B/Binax Inc. 80 30 12 39 (27) 25 (28) 0.074
Quick S-Inﬂu A/B/Seiken 80 17 18 37 (27) 37 (28) 0.997
Inﬂu-A&B Respi-Strip/Coris Bioconcept 80 43 16 40 (26) 23 (24) 0.014
Actim Inﬂuenza A&B/Medix Biochemica 80 53 32 41 (28) 28 (25) 0.033
SD, standard deviation.
aLogistic regression.
TABLE 3. In vitro sensitivity of the near-patient assays for
inﬂuenza A and B viruses in comparison to an in-house
ELISA and inﬂuenza A virus-speciﬁc RT-PCR
Diagnostic
assay/manufacturer
Lowest concentration of stock virus yielding
a positive result (TCID50/mL)
A/Wisconsin/67/05
(H3N2)
A/New
Caledonia/20/99
(H1N1)
B/Jiangsu/
10/03
Binax Now Inﬂuenza
A&B/Binax Inc.
104 105 103
Inﬂu-A&B Respi-Strip/Coris
Bioconcept
104 106 103
Actim Inﬂuenza A&B/Medix
Biochemica
103 105 102
Antigen-ELISA/in-house 103 105 103
RT-PCR/in-house 10)3 10)2 ND
ND, not done because RT-PCR is only speciﬁc for inﬂuenza A viruses; TCID50,
50% tissue culture infective dose.
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FIG. 1. Estimated sensitivity of near-patient assays in relation to the
patient’s age. Curves were obtained from logistic regression analysis
and plotted with the use of the software SigmaPlot 10.0 (Systat Soft-
ware GmbH, Erkratti, Germany).
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study demonstrated unambiguously, for the ﬁrst time, that
the effectiveness of near-patient assays for the diagnosis of
inﬂuenza A/H3N2 virus infection decreases signiﬁcantly with
increasing age of the patient. The low sensitivity of near-
patient assays for the diagnosis of inﬂuenza, in comparison to
virus isolation or RT-PCR, does not allow a reliable exclu-
sion of the diagnosis of inﬂuenza. The present study supports
the belief that antiviral therapy and additional diagnostic
procedures should not be withheld in cases where inﬂuenza
is clinically suspected on the basis of a negative near-patient
assay, particularly in adult patients. On the other hand, the
high speciﬁcity of near-patient assays, together with the
advantage of results being available within 30 min, may pro-
vide important information for the clinical evaluation of
patients with an acute respiratory illness, provided that the
result of the near-patient assay is positive.
Reliable and rapid identiﬁcation of inﬂuenza cases is of
particular importance in elderly patients. The age group
>65 years is at high risk of a severe course of inﬂuenza; 90%
of all inﬂuenza-related deaths occur in this age group [1],
and the estimated risk of inﬂuenza-related hospitalizations is
19–56 per 10 000 individuals during the inﬂuenza season
[17]. Highly effective antiviral drugs are available for the
treatment of inﬂuenza but must be administered within 48 h
after onset of the disease and are effective only against inﬂu-
enza viruses. Respiratory syncytial virus co-circulates fre-
quently with inﬂuenza viruses, causing a signiﬁcant disease
burden also in elderly patients, and the clinical features are
difﬁcult to distinguish from those of inﬂuenza [18]. The use-
fulness of near-patient assays is particularly low in the
elderly. As a consequence, a considerable number of patients
are treated unnecessarily and ineffectively with antiviral or
antibacterial drugs, or are exposed to radiation due to addi-
tional diagnostic procedures. Therefore, the importance of
annual vaccination against inﬂuenza, for elderly patients and
their care-givers, cannot be overemphasized [19].
In our previous study, the detection rate for inﬂuenza A
viruses was clearly lower when testing respiratory specimens
from adults than when testing specimens from young
children, even with the use of highly sensitive assays such as
RT-PCR [9]. The results of previous evaluations of near-
patient assay sensitivity, with regard to patient age, were
discordant. Fader [12] noted a clear decrease in assay sensi-
tivity with increasing age, whereas Weinberg and Walker
[20] did not, although both studies evaluated the same assay
(Binax Now; Binax Inc., Portland, ME, USA). The respiratory
specimens used were heterogeneous (nasal washes, nasal
aspirates and bronchoalveolar lavages) and differed between
the two studies. In adults, nasal washes are more convenient
to collect than nasopharyngeal aspirates, but a diluting effect
is inherent in this technique of sample collection and results
TABLE 4. Results of near-patient assays for the diagnosis of inﬂuenza virus infection in relation to inﬂuenza A virus RNA
concentration in clinical samples
Near-patient assay/manufacturer
No. of samples
available
Median concentration of
inﬂuenza A virus RNA
(copies/mL)
p-valuea
ROC curve cut-off
for 100% sensitivity
(copies/mL)Negative Positive
Binax Now Inﬂuenza A&B/Binax Inc. 28 1.7 · 103 5.1 · 104 0.002 2.7 · 103
Quick S-Inﬂu A/B/Seiken 24 1.9 · 103 8.0 · 104 0.048 2.6 · 103
Inﬂu-A&B Respi-Strip/Coris Bioconcept 22 2.1 · 103 7.2 · 104 0.014 9.3 · 102
Actim Inﬂuenza A&B/Medix Biochemica 32 3.4 · 103 3.1 · 104 0.004 6.8 · 102
ROC, receiver operating characteristic.
aMann–Whitney U-test.
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FIG. 2. Receiver operating characteristic (ROC) curves for predic-
tion of a positive result of near-patient assays for detection of
inﬂuenza A virus in clinical samples from patients with laboratory-
conﬁrmed inﬂuenza A virus infection.
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in lower detection rates [20]. The strength of the present
study is the use of comparable samples; all clinical specimens
were collected with an identical technique by experienced
and well-trained physicians, with the use of a standardized
sampling kit. Furthermore, in vitro evaluation of near-patient
assay sensitivity with the use of virus stock preparations
could be conﬁrmed by determination of the inﬂu-
enza A/H3N2 virus RNA concentrations in clinical samples.
These features reduce the potential for bias and support the
notion that the ﬁndings can be generalized.
The present study also has limitations. Only samples posi-
tive for inﬂuenza A/H3N2 viruses were tested, for the pur-
pose of standardization, and conclusions cannot be drawn
concerning the sensitivity of near-patient assays for inﬂu-
enza A/H1N1 and B viruses. In the present study, the in vitro
sensitivity of near-patient assays differed for inﬂu-
enza A/H3N2, A/H1N1 and B viruses. Direct comparison of
the in vitro sensitivities of near-patient assays with that of
RT-PCR has to be made with caution, because of the use
of cell culture-grown inﬂuenza strains. Cell culture prepara-
tions contain a considerable amount of defective virus parti-
cles. Different structures of these particles may be detected
by use of near-patient assays and RT-PCR, and degradation
of virus particles follows different kinetics in cell culture
than in the human host. Furthermore, the assay was evalu-
ated retrospectively in a virological laboratory, as in most
previous studies [20,21]. The laboratory setting allows a
more standardized inter-assay comparison, but transfer of
respiratory secretions into the medium used for preserva-
tion of virus and solubilization of mucus adds a dilution step
that may reduce the detection rates achievable with near-
patient assays. In the present investigation, preservation of
nasopharyngeal swabs in transport medium resulted in a
ﬁnal dilution of one log titre. This dilution effect cannot
explain the differences in sensitivity observed between age
groups or the differences among the four near-patient
assays. Nevertheless, the effectiveness of near-patient assays
for the diagnosis of inﬂuenza A/H3N2 virus infections may
be expected to be somewhat higher when bedside testing is
performed.
In conclusion, the sensitivity of near-patient assays is not
only signiﬁcantly lower than that of inﬂuenza virus-speciﬁc
RT-PCR, but is also signiﬁcantly affected by the patient’s age.
Antiviral therapy and additional diagnostic procedures should
not be withheld on the basis of a near-patient assay with a
negative result, particularly in adult patients in whom inﬂu-
enza is clinically suspected. Because of the high speciﬁcity of
the near-patient assay, however, a positive test result may
be helpful in making management decisions, including those
concerning administration of antiviral therapy.
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